Yishuo Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8223240/publications.pdf

Version: 2024-02-01

687363 501196 30 813 13 28 citations h-index g-index papers 31 31 31 1452 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Genetic polymorphisms at 19q13.33 are associated with [â^'2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer. Prostate, 2021, 81, 971-982.	2.3	4
2	The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer. Frontiers in Oncology, 2021, 11, 752860.	2.8	6
3	A Germline Variant at 8q24 Contributes to the Serum p2PSA Level in a Chinese Prostate Biopsy Cohort. Frontiers in Oncology, 2021, 11, 753920.	2.8	2
4	HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria. European Urology Focus, 2020, 6, 284-291.	3.1	27
5	The study on copy number alteration of clear cell renal cancer in Chinese population. Journal of Cancer, 2020, 11, 16-24.	2.5	2
6	Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy. Frontiers in Oncology, 2020, 10, 565382.	2.8	10
7	Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. European Urology Oncology, 2020, 3, 224-230.	5.4	41
8	Family history is significantly associated with prostate cancer and its early onset in Chinese population. Prostate, 2019, 79, 1762-1766.	2.3	6
9	Concept and benchmarks for assessing narrowâ€sense validity of genetic risk score values. Prostate, 2019, 79, 1099-1105.	2.3	18
10	Systematic evaluation of cancerâ€specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts. Cancer Medicine, 2019, 8, 3196-3205.	2.8	22
11	Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer. Journal of Cancer, 2019, 10, 6761-6766.	2.5	37
12	Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. European Urology, 2019, 75, 743-749.	1.9	138
13	A comprehensive evaluation of <i>CHEK2</i> germline mutations in men with prostate cancer. Prostate, 2018, 78, 607-615.	2.3	57
14	Genome-wide Association Study (GWAS) of Germline Copy Number Variations (CNVs) Reveal Genetic Risks of Prostate Cancer in Chinese population. Journal of Cancer, 2018, 9, 923-928.	2.5	13
15	Germline mutations in <i>PPFIBP2</i> are associated with lethal prostate cancer. Prostate, 2018, 78, 1222-1228.	2.3	12
16	Germline mutations in <scp>DNA</scp> repair genes are associated with bladder cancer risk and unfavourable prognosis. BJU International, 2018, 122, 808-813.	2.5	15
17	A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy. Annals of Clinical and Laboratory Science, 2018, 48, 18-28.	0.2	1
18	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, 2017, 71, 740-747.	1.9	256

#	Article	IF	CITATIONS
19	Elevated hardness of peripheral gland on real-time elastography is an independent marker for high-risk prostate cancers. Radiologia Medica, 2017, 122, 944-951.	7.7	2
20	Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. Prostate, 2017, 77, 1221-	1 22 9.	26
21	Validation of the novel susceptibility loci for prostate cancer in a Chinese population. Oncology Letters, 2017, 15, 2567-2573.	1.8	3
22	The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent. Oncotarget, 2017, 8, 30151-30161.	1.8	10
23	Germline genetic variations in PDZD2 and ITPR2 genes are associated with clear cell renal cell carcinoma in Chinese population. Oncotarget, 2017, 8, 24196-24201.	1.8	5
24	Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases. Asian Journal of Andrology, 2016, 18, 525.	1.6	11
25	The effect of discrepancy between radiologic size and pathologic tumor size in renal cell cancer. SpringerPlus, 2016, 5, 899.	1.2	10
26	Genetic scores based on risk-associated single nucleotide polymorphisms (SNPs) can reveal inherited risk of renal cell carcinoma. Oncotarget, 2016, 7, 18631-18637.	1.8	7
27	Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss. Oncotarget, 2016, 7, 34752-34758.	1.8	6
28	Clinically available RNA profiling tests of prostate tumors: utility and comparison. Asian Journal of Andrology, 2016, 18, 575.	1.6	14
29	The Evaluation of the Risk Factors for Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence after Transurethral Resection (TURBt) in Chinese Population. PLoS ONE, 2015, 10, e0123617.	2.5	28
30	Plasma genistein and risk of prostate cancer in Chinese population. International Urology and Nephrology, 2015, 47, 965-970.	1.4	24